These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 19339952)

  • 1. Safety concerns about CCR5 as an antiviral target.
    Telenti A
    Curr Opin HIV AIDS; 2009 Mar; 4(2):131-5. PubMed ID: 19339952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CCR5: no longer a "good for nothing" gene--chemokine control of West Nile virus infection.
    Lim JK; Glass WG; McDermott DH; Murphy PM
    Trends Immunol; 2006 Jul; 27(7):308-12. PubMed ID: 16753343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The chemokine system and CCR5 antagonists: potential in HIV treatment and other novel therapies.
    Dhami H; Fritz CE; Gankin B; Pak SH; Yi W; Seya MJ; Raffa RB; Nagar S
    J Clin Pharm Ther; 2009 Apr; 34(2):147-60. PubMed ID: 19250135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New kinds of AIDS drugs inhibit HIV entry into the cell. Entry inhibitors soon for oral administration].
    Fätkenheuer G
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():46-8. PubMed ID: 16385874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CCR5 antagonism in HIV infection: ways, effects, and side effects.
    Corbeau P; Reynes J
    AIDS; 2009 Sep; 23(15):1931-43. PubMed ID: 19724192
    [No Abstract]   [Full Text] [Related]  

  • 6. CCR5 antagonists for the treatment of HIV.
    Barber CG
    Curr Opin Investig Drugs; 2004 Aug; 5(8):851-61. PubMed ID: 15600241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [CCR5 antagonists: a new class of antiretrovirals].
    Peytavin G; Calvez V; Katlama C
    Therapie; 2009; 64(1):9-16. PubMed ID: 19463248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beyond HIV infection: Neglected and varied impacts of CCR5 and CCR5Δ32 on viral diseases.
    Ellwanger JH; Kulmann-Leal B; Kaminski VL; Rodrigues AG; Bragatte MAS; Chies JAB
    Virus Res; 2020 Sep; 286():198040. PubMed ID: 32479976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients.
    Lalezari J; Yadavalli GK; Para M; Richmond G; Dejesus E; Brown SJ; Cai W; Chen C; Zhong J; Novello LA; Lederman MM; Subramanian GM
    J Infect Dis; 2008 Mar; 197(5):721-7. PubMed ID: 18266604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CCR5 antagonists in the treatment of HIV-infected persons: is their cancer risk increased, decreased, or unchanged.
    McNiff T; Dezube BJ
    AIDS Read; 2009; 19(6):218-22, 224. PubMed ID: 19642239
    [No Abstract]   [Full Text] [Related]  

  • 11. A genetic basis for human susceptibility to West Nile virus.
    Diamond MS; Klein RS
    Trends Microbiol; 2006 Jul; 14(7):287-9. PubMed ID: 16750369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Entry inhibitors: a race to the finish line.
    Proj Inf Perspect; 2006 Jan; (40):7-12. PubMed ID: 16718905
    [No Abstract]   [Full Text] [Related]  

  • 13. [The impact of a new family among the therapeutic strategies: the immunologist's point of view].
    Corbeau P
    Med Mal Infect; 2009 Oct; 39(10 Suppl 1):H13-5. PubMed ID: 19837346
    [No Abstract]   [Full Text] [Related]  

  • 14. A new era in HIV treatment: the entry inhibitors.
    Berger DS
    Posit Aware; 2005; 16(1):51-3. PubMed ID: 17390505
    [No Abstract]   [Full Text] [Related]  

  • 15. CCR5 entry inhibitor problems: no clear answers yet.
    James JS
    AIDS Treat News; 2005; (416):4-5. PubMed ID: 16388544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing theoretical risk and benefit suggested by genetic association studies of CCR5: experience in a drug development programme for maraviroc.
    Wheeler J; McHale M; Jackson V; Penny M
    Antivir Ther; 2007; 12(2):233-45. PubMed ID: 17503665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term safety study of vicriviroc presented.
    Proj Inf Perspect; 2008 Dec; (47):13. PubMed ID: 19227564
    [No Abstract]   [Full Text] [Related]  

  • 18. The relative activity of "function sparing" HIV-1 entry inhibitors on viral entry and CCR5 internalization: is allosteric functional selectivity a valuable therapeutic property?
    Muniz-Medina VM; Jones S; Maglich JM; Galardi C; Hollingsworth RE; Kazmierski WM; Ferris RG; Edelstein MP; Chiswell KE; Kenakin TP
    Mol Pharmacol; 2009 Mar; 75(3):490-501. PubMed ID: 19064629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [CCR5 inhibitors. A new point of attack for HIV infection].
    Heinzl S
    Med Monatsschr Pharm; 2007 Dec; 30(12):434-8; quiz 439-40. PubMed ID: 18196845
    [No Abstract]   [Full Text] [Related]  

  • 20. Looking back at entry inhibition. CCR5 blockers in GMHC Treatment issues, 1996-2006.
    GMHC Treat Issues; 2006; 20(8-12):4-7. PubMed ID: 17569161
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.